Fol. Biol. 2006, 52, 21-33
https://doi.org/10.14712/fb2006052010021
Elevated and Deregulated Expression of HDAC3 in Human Astrocytic Glial Tumours
References
1. 2004) Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells. Eur. J. Cancer 40, 1073-1081.
< , T., Appelskog, I. B., Ammerpohl, O., Ekstrom, T. J., Almqvist, P. M. (https://doi.org/10.1016/j.ejca.2003.11.034>
2. 2001) Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 79, 243-252.
< , N. R., Wang, A. H., Yang, X. J. (https://doi.org/10.1139/o01-032>
3. 2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38879-38887.
< , C. S., Weng, S. C., Tseng, P. H., Lin, H. P. (https://doi.org/10.1074/jbc.M505733200>
4. 2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737-749.
< , A. J., van Gennip, A. H., Caron, H. N., Kemp, S., van Kuilenburg, A. B. (https://doi.org/10.1042/bj20021321>
5. 1996) p300 and CBP as transcriptional regulators and targets of oncogenic events. Biol. Chem. 377, 685-688.
, R. (
6. 2001) Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem. 276, 35826-35835.
< , W., Dequiedt, F., Fillion, M., Hendzel, M. J., Voelter, W., Verdin, E. (https://doi.org/10.1074/jbc.M104935200>
7. 2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/NCoR. Mol. Cell 9, 45-57.
< , W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., Verdin, E. (https://doi.org/10.1016/S1097-2765(01)00429-4>
8. 2004) Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem. Pharmacol. 68, 1199-1208.
< , M., Wang, C., Zhang, X., Pestell, R. G. (https://doi.org/10.1016/j.bcp.2004.05.037>
9. 2003) Interaction of 5-aza-2’-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3σ, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs 14, 193-202.
< , J., Shaker, S., Primeau, M., Hurtubise, A., Momparler, R. L.. (https://doi.org/10.1097/00001813-200303000-00002>
10. 2005) Regulation of nuclear translocation of HDAC3 by IκBαis required for TNF-inhibition of PPARγ function. J. Biol. Chem. 281, 4540-4547.
< , Z., He, Q., Peng, B., Chiao, P., Ye, J. (https://doi.org/10.1074/jbc.M507784200>
11. 2000) Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. USA 97, 7835-7840.
< , C. M., Schreiber, S. L. (https://doi.org/10.1073/pnas.140199597>
12. 2005) Small molecule regulation of Sir2 protein deacetylases. FEBS J. 272, 4607-4616.
< , O., Smith, B. C., Denu, J. M. (https://doi.org/10.1111/j.1742-4658.2005.04862.x>
13. 2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell Biol. 21, 6091-6101.
< , M. G., Barak, O., Lazar, M. A. (https://doi.org/10.1128/MCB.21.18.6091-6101.2001>
14. 1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387, 43-48.
< , T., Lavinsky, R. M., Mullen, T. M., Soderstrom, M., Laherty, C. D., Torchia, J., Yang, W. M., Brard, G., Ngo, S. D., Davie, J. R., Seto, E., Eisenman, R. N., Rose, D. W., Glass, C. K., Rosenfeld, M. G. (https://doi.org/10.1038/387043a0>
15. 2006) How transcriptional and epigenetic programmes are played out on an individual mammalian gene cluster during lineage commitment and differentiation. Biochem. Soc. Symp. 11-22.
, D. R., Vernimmen, D., De Gobbi, M., Anguita, E., Hughes, J., Buckle, V., Iborra, F., Garrick, D., Wood, W. G. (
16. 2003) The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol. Cell Biol. 23, 5122-5131.
< , T., Lazar, M. A. (https://doi.org/10.1128/MCB.23.15.5122-5131.2003>
17. 2004) p300/CBP and cancer. Oncogene 23, 4225-4231.
< , N. G., Ozdag, H., Caldas, C. (https://doi.org/10.1038/sj.onc.1207118>
18. 2001) Translating the histone code. Science 293, 1074-1080.
< , T., Allis, C. D. (https://doi.org/10.1126/science.1063127>
19. 2004) Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 59, 1174-1180.
< , J. H., Shin, J. H., Kim, I. H. (https://doi.org/10.1016/j.ijrobp.2004.03.001>
20. 1997) Locus control regions: overcoming heterochromatin-induced gene inactivation in mammals. Curr. Opin. Genet. Dev. 7, 614-619.
< , D., Festenstein, R. (https://doi.org/10.1016/S0959-437X(97)80008-1>
21. Kleihues, P., Cavenee, W. K. (2000). World Health Orgnization Classification of Tumours of the Nervous System. Lyon: WHO/IARC.
22. 1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
< , U. K. (https://doi.org/10.1038/227680a0>
23. 2001) Transcriptional regulation in acute promyelocytic leukemia. Oncogene 20, 7204-7215.
< , R. J., Sternsdorf, T., Tini, M., Evans, R. M. (https://doi.org/10.1038/sj.onc.1204853>
24. 2002) Cyclin D1 is a ligand-independent Co-repressor for thyroid hormone receptors. J. Biol. Chem. 277, 28733-28741.
< , H. M., Zhao, L., Cheng, S. Y. (https://doi.org/10.1074/jbc.M203380200>
25. Longworth, M. S., Laimins, L. A. (2006) Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene. Epub ahead of print.
26. 2004) Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J. Immunol. 173, 3979-3990.
< , U., Will, J., Varin, A., Hoelzer, D., Herbein, G. (https://doi.org/10.4049/jimmunol.173.6.3979>
27. 1993) Measurement of co-localisation of objects in dual colour confocal images. J. Microsc. 169, 375-382.
< , E. M. M., Verbeek, F. J., Aten, J. A. (https://doi.org/10.1111/j.1365-2818.1993.tb03313.x>
28. 1980) Demonstration of enzymes in cells cultured on semipermeable membrane in a double chamber. Histochemistry 65, 325-327.
< , V., Elleder, M. (https://doi.org/10.1007/BF00493183>
29. 2001) CBP, a transcriptional coactivator and acetyltransferase. Biochem. Cell. Biol. 79, 253-266.
< , K. J., Hendzel, M. J. (https://doi.org/10.1139/o01-076>
30. 2006) Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 16, 125-136.
< , K. P., O’Neill, L. P., Turner, B. M. (https://doi.org/10.1016/j.gde.2006.02.015>
31. 1995) Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376, 348-351.
< , F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C., Masuno, M., Tommerup, N., van Ommen, G. J., Goodman, R. H., Peters, D. J., et al. (https://doi.org/10.1038/376348a0>
32. 2002) Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. 19, 77-81.
< , H., Murakami, H., Ohshima, Y., Murakami, M., Yamazaki, I., Tamura Y., Mima, T., Satone, A., Ide, W., Hashimoto, I., Kamada, H. (https://doi.org/10.1007/BF02478931>
33. 2004) Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol. (Berl). 107, 523-531.
< , H., Murakami, H., Kumagai, M., Nakasato, M., Yamauchi, S., Matsuyama, N., Tamura, Y., Satone, A., Ide, W., Hashimoto, I., Kamada, H. (https://doi.org/10.1007/s00401-004-0841-3>
34. 2004) Identification and quantification of arsC genes in environmental samples by using real-time PCR. J. Microbiol. Methods 58, 335-349.
< , Y., Polishchuk, E. A., Radoja, U., Cullen, W. R. (https://doi.org/10.1016/j.mimet.2004.04.015>
35. 1999) Epigenetics: regulation through repression. Science 286, 481-486.
< , A. P., Matzke, M. A. (https://doi.org/10.1126/science.286.5439.481>
36. 1997) Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 272, 28001-28007.
< , W. M., Yao, Y. L., Sun, J. M., Davie, J. R., Seto, E. (https://doi.org/10.1074/jbc.272.44.28001>
37. 1996) A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol. Cell. Biol. 16, 5458-5465.
< , I., Harding, H. P., Atkins, G. B., Horlein, A., Glass, C. K., Rosenfeld, M. G., Lazar, M. A. (https://doi.org/10.1128/MCB.16.10.5458>
38. 2005) Two catalytic domains are required for protein deacetylation. J. Biol. Chem. 281, 2401-2404.
< , Y., Gilquin, B., Khochbin, S., Matthias, P. (https://doi.org/10.1074/jbc.C500241200>
39. 2006) Characterization of the two catalytic domains in histone deacetylase 6. Biochem. Biophys. Res. Commun. 341, 45-50.
< , H., Wu, Y., Navre, M., Sang, B. C.. (https://doi.org/10.1016/j.bbrc.2005.12.144>